Science Publications

Sign Up
Sign In
Submit
Current Research in Public Health
Cite This Article Share Download PDF XML
  1. Home
  2. Journals
  3. Current Research in Public Health
  4. Archive
  5. Volume 5, Issue 1, 2025
  6. Article
Case Report Open Access February 24, 2025

Pembrolizumab-induced myelitis in stage 4 renal clear cell carcinoma: a case report

Vonny Fibrianty Goenawan 1, Vivien Puspitasari 1,*, Mary Christina Elsa 2 and Ratna Sutanto 3
1
Department of Neurology, Faculty of Medicine, Universitas Pelita Harapan – Siloam Hospital Lippo Village, Tangerang, Indonesia
2
Department of Neurology, Faculty of Medicine, Universitas Pelita Harapan, Karawaci, Tangerang, Indonesia
3
Department of Radiology, Faculty of Medicine, Universitas Pelita Harapan - Siloam Hospital Lippo Village, Tangerang, Indonesia
Publihed in: Current Research in Public Health (Volume 5, Issue 1, 2025)
Page(s): 46-50
DOI: 10.31586/ojms.2025.1259
Received
November 29, 2024
Revised
January 26, 2025
Accepted
February 11, 2025
Published
February 24, 2025
Keywords
Pembrolizumab; Immune Checkpoint Inhibitor; Myelitis; Renal Cell Carcinoma
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright: Copyright © The Author(s), 2025. Published by Scientific Publications
Article metrics
Views
278
Downloads
66

Cite This Article

APA Style
Goenawan, V. F. , Goenawan, V. F. Puspitasari, V. , Puspitasari, V. Elsa, M. C. , & Elsa, M. C. (2025). Pembrolizumab-induced myelitis in stage 4 renal clear cell carcinoma: a case report. Current Research in Public Health, 5(1), 46-50. https://doi.org/10.31586/ojms.2025.1259
ACS Style
Goenawan, V. F. ; Goenawan, V. F. Puspitasari, V. ; Puspitasari, V. Elsa, M. C. ; Elsa, M. C. Pembrolizumab-induced myelitis in stage 4 renal clear cell carcinoma: a case report. Current Research in Public Health 2025 5(1), 46-50. https://doi.org/10.31586/ojms.2025.1259
Chicago/Turabian Style
Goenawan, Vonny Fibrianty, Vonny Fibrianty Goenawan. Vivien Puspitasari, Vivien Puspitasari. Mary Christina Elsa, and Mary Christina Elsa. 2025. "Pembrolizumab-induced myelitis in stage 4 renal clear cell carcinoma: a case report". Current Research in Public Health 5, no. 1: 46-50. https://doi.org/10.31586/ojms.2025.1259
AMA Style
Goenawan VF, Goenawan VFPuspitasari V, Puspitasari VElsa MC, Elsa MC. Pembrolizumab-induced myelitis in stage 4 renal clear cell carcinoma: a case report. Current Research in Public Health. 2025; 5(1):46-50. https://doi.org/10.31586/ojms.2025.1259 
@Article{crph1259,
AUTHOR = {Goenawan, Vonny Fibrianty and Puspitasari, Vivien and Elsa, Mary Christina and Sutanto, Ratna},
TITLE = {Pembrolizumab-induced myelitis in stage 4 renal clear cell carcinoma: a case report},
JOURNAL = {Current Research in Public Health},
VOLUME = {5},
YEAR = {2025},
NUMBER = {1},
PAGES = {46-50},
URL = {https://www.scipublications.com/journal/index.php/OJMS/article/view/1259},
ISSN = {2831-5162},
DOI = {10.31586/ojms.2025.1259},
ABSTRACT = {Pembrolizumab, an immune checkpoint inhibitor targeting the programmed cell death 1 (PD-1) protein, is widely used for renal cell carcinoma but rarely causes central nervous system adverse events such as myelitis. A 58-year-old woman with stage IV renal clear cell carcinoma developed radiating hip pain, paresthesia, hypoesthesia (T10 and below), constipation, urinary retention, and sudden right-eye blurred vision one month after her sixth cycle of pembrolizumab and lenvatinib. Neurologic examination revealed asymmetrical inferior paraparesis, upper motor neuron signs, and right eye papilledema. MRI demonstrated patchy hyperintensity on C2-C6 and T2-T5, supportive of myelitis. Intravenous methylprednisolone was initiated, leading to pain relief and motor improvement. This is the first reported case of pembrolizumab-induced myelitis in Indonesia, emphasizing the importance of early recognition and corticosteroid therapy for optimal recovery.},
}
%0 Journal Article
%A Goenawan, Vonny Fibrianty
%A Puspitasari, Vivien
%A Elsa, Mary Christina
%A Sutanto, Ratna
%D 2025
%J Current Research in Public Health

%@ 2831-5162
%V 5
%N 1
%P 46-50

%T Pembrolizumab-induced myelitis in stage 4 renal clear cell carcinoma: a case report
%M doi:10.31586/ojms.2025.1259
%U https://www.scipublications.com/journal/index.php/OJMS/article/view/1259

TY  - JOUR
AU  - Goenawan, Vonny Fibrianty
AU  - Puspitasari, Vivien
AU  - Elsa, Mary Christina
AU  - Sutanto, Ratna
TI  - Pembrolizumab-induced myelitis in stage 4 renal clear cell carcinoma: a case report
T2  - Current Research in Public Health
PY  - 2025
VL  - 5
IS  - 1
SN  - 2831-5162
SP  - 46
EP  - 50
UR  - https://www.scipublications.com/journal/index.php/OJMS/article/view/1259
AB  - Pembrolizumab, an immune checkpoint inhibitor targeting the programmed cell death 1 (PD-1) protein, is widely used for renal cell carcinoma but rarely causes central nervous system adverse events such as myelitis. A 58-year-old woman with stage IV renal clear cell carcinoma developed radiating hip pain, paresthesia, hypoesthesia (T10 and below), constipation, urinary retention, and sudden right-eye blurred vision one month after her sixth cycle of pembrolizumab and lenvatinib. Neurologic examination revealed asymmetrical inferior paraparesis, upper motor neuron signs, and right eye papilledema. MRI demonstrated patchy hyperintensity on C2-C6 and T2-T5, supportive of myelitis. Intravenous methylprednisolone was initiated, leading to pain relief and motor improvement. This is the first reported case of pembrolizumab-induced myelitis in Indonesia, emphasizing the importance of early recognition and corticosteroid therapy for optimal recovery.
DO  - Pembrolizumab-induced myelitis in stage 4 renal clear cell carcinoma: a case report
TI  - 10.31586/ojms.2025.1259
ER  -